321 results about "Vancomycin" patented technology

This invention provides a method of detecting pathogens comprising the steps of: (a) contacting a sufficient amount of biofunctional magnetic nanoparticles with an appropriate sample for an appropriate period of time to permit the formation of complexes between the pathogens in the sample and the nanoparticles; (b) using a magnetic field to aggregate said complexes; and (c) detecting said complexes. The method may further comprise the additional step of removing said complexes. The biofunctional magnetic nanoparticles are preferably a conjugate of vancomycin and FePt. The pathogens may be bacteria or viruses, and the sample may be a solid, liquid, or gas. Detection may involve conventional fluorescence assay, enzyme-linked immunosorbent assay (ELISA), optical microscope, electron microscope, or a combination thereof. The sensitivity of detection for the method is at least as low as 10 colony forming units (cfu) of the pathogens in one milliliter of solution within one hour.

The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.

Vancomycin-containing compositions substantially free of precipitation after at least about 12 months of storage at refrigerated or ambient conditions are disclosed. The compositions include vancomycin or a pharmaceutically acceptable salt thereof; a polar solvent including propylene glycol, polyethylene glycol and mixtures thereof; lactic acid, a lactate salt, or mixtures thereof; and optionally, a pH adjuster in an amount sufficient to maintain a pH of the compositions at from about 3 to about 8.

The invention relates to a method for separating vancomycin. The method comprises the following steps: (1) carrying out the column chromatography elution on the vancomycin fermentation liquor in a hydrochloric acid aqueous solution mobile phase macropore absorptive resin chromatographic column containing alcohol so as to obtain vancomycin aqueous solution; (2) adding NH4HCO3 into the hydrochloricacid vancomycin aqueous solution to form precipitate, adjusting the pH value to between 7.5 and 8.5 through ammonia water, and stirring and standing the solution; and (3) obtaining a vancomycin crudeproduct with the content of vancomycin chromatographic purity not less than 80 percent through filtration separation and alcohol top washing. The method is simple and has high yield. The content of the vancomycin chromatographic purity is not less than 80 percent; and the titer of a vancomycin wet product at least reaches 500 mu g/mg.

Disclosed is a cornea middle term preserving fluid which comprises RPMI 1640 culture liquid, chondroitin sulfate, hyaluronic acid, HEPES cushioning liquid, dexamethasone, low-molecular-weight seaweed polysaccharides, Tobramycin or vancomycin, the preserving fluid has stabilized cell activity during storage period, and higher endothelial cell metabolizing function can be maintained than the US's Opthiol.

The invention discloses a VEGF and vancomycin-supported multilayer local slow release microsphere preparation with sodium alginate and chitosan as a carrier, a preparation method of the microsphere preparation, and an application of the microsphere preparation in the preparation of medicines for treating bone defects, bone tissue regeneration and wound healing, and belongs to the technical field of medicine slow release microspheres. In the invention, a core sphere is prepared through an instillation process, and other multilayer microspheres are prepared according to a positive and negative charge attraction and layer-by-layer self assembling principle. Sodium alginate and chitosan are natural polymer polysaccharides, chitosan is a polycation polymer material, and the side chain structure of chitosan contains a large number of free amino groups; and sodium alginate is a polyanion material, the molecular side chain of sodium alginate contains a large number of carboxyl groups, sodium alginate and chitosan undergo a complexing reaction through attraction of positive and negative charges, and the core-shell multilayer slow release medicine multilayer sphere is formed by sequentially wrapping according to the layer-by-layer self assembling principle, so multilayer slow release microsphere preparation can promote local angiogenesis, improve blood circulation and control local infection.

A method and formulation for preparing spray dried vancomycin. In various embodiment, the formulation includes vancomycin HCl (10-20%) and one or more of the following PEG (0-5%), mannitol (0-5%), ethanol (0-10%), and a citrate buffer. Spray dried vancomycin has favorable reconstitution times and water content.

In one aspect, the invention provides a stabilized lipid-based glycopeptide antibiotic composition and a process for producing the same. In another aspect, the invention provides methods for treating a bacterial pulmonary infection by administering to a subject in need thereof a therapeutically effective amount of the stabilized lipid-based glycopeptide antibiotic composition.

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

The invention relates to azaphilones compounds in marine fungus HK1-6 and an application of the azaphilones compounds as an MRSA-resistant drug, in particular to secondary metabolites 1-4 produced bymarine fungus Penicillium sp.HK1-6 or pharmaceutically acceptable salt. The compounds 1-4 show very high antibacterial activity for MRSA (such as S. aureus ATCC4330 and S. aureus ATCC33591) and VER (such as E. faecalis ATCC51299), MIC is smaller than or equal to 12.5 mu g/mL, the MIC of a compound 2 for E. faecalis ATCC51299 is one times higher than that of positive drug vancomycin, and the compounds have good prospects to be developed into drugs resisting drug-resistant bacteria, lead compounds of drugs and candidate drugs.

The invention provides an antibiotic controlled freed porous bone replacing material and a preparation method thereof. The antibiotic controlled freed porous bone replacing material is characterized by consisting of polycaprolactone, nano tricalcium phosphate, chitosan/vancomycin microsphere with sodium alginate coating, and tobramycin. The preparation method comprises the following steps: dissolving the chitosan in glacial acetic acid solution, dissolving the vancomycin in the glacial acetic acid solution, spraying and drying to prepare the chitosan/vancomycin microsphere; moving the microsphere into the sodium alginate solution; dissolving the microsphere and the nano tricalcium phosphate powder in dichloromethane solution of the polycaprolactone, adding a pore-forming agent, stirring uniformly, extruding and forming, putting the formed material in deionized water after the dichloromethane is volatilized, dissolving out the pore-forming agent, and obtaining the porous material; and immersing the porous material into tobramycin sulfate solution, and drying. The invention has the advantages that the vancomycin and the tobramycin can be released simultaneously in the early stage. The two antibiotics can kill the intractable bacteria of methicillin-resistant Staphylococcus aureus and the like, which are common clinically and infected chronically by bones.

The invention belongs to the technical field of biomedical materials, and discloses an anti-infection mineralized collagen and calcium sulfate bone repair material and a preparation method thereof. The material is composite powder comprising 2-5wt% of mineralized collagen, 5-15wt% of vancomycin, 20-25wt% of calcium sulfate dihydrate and the balance alpha-type calcium sulfate hemihydrate. The alpha-type calcium sulfate hemihydrate is prepared by a hydrothermal method, the mineralized collagen is prepared by a biological mineralization method, and the alpha-type calcium sulfate hemihydrate, the mineralized collagen, the vancomycin and the coagulant calcium sulfate dihydrate are mixed to prepare the anti-infection mineralized collagen and calcium sulfate bone repair material with a certain component ratio. When the liquid/solid ratio is 0.5-0.8mL/g, the material has a fine self-setting performance, is degradable, slowly releases medicines, and is anti-infection. Besides, the material has fine biocompatibility and can promote adhesion and spreading of osteoblasts.

The invention relates to the field of drugs, in particular to a detection method for simultaneously determining content of vancomycin and tobramycin in tissue drainage liquid. A method for simultaneously determining content of vancomycin and tobramycin in tissue drainage liquid through an ultrahigh performance liquid chromatography-triple quadrupole mass spectrometry (UPLC-TQD) coupling techniquecomprises the following steps of: 1) preparing reference samples; 2) preparing internal standard solution; 3) preparing sample solution; 4) preparing mobile-phase solution; 5) setting chromatographicconditions; 6) optimizing mass spectrometric conditions; 7) determining the samples; 8) preparing gradient-concentration reference sample solution; 9) preparing a standard curve; and 10) analyzing and computing data. The method has the characteristics that: 1) the method is advanced; 2) the method is rapid and high-efficiency the loss is low; and 3) the clinical application prospect and the effect are good.

The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.

The invention belongs to the field of antibiotic preparation technologies, and more specifically relates to a preparation method of vancomycin with high purity. The preparation method comprises following steps: a destaining solution of vancomycin is subjected to column chromatography in a chromatography media, wherein the chromatography media is UniPMM50CAR, the NH4HCO3 mass concentration of a mobile phase of column chromatography is 0.2 to 0.7%; when absorbance rises to 40 at a detection wavelength of 280nm, chromatography liquids are collected segment by segment, the pH value of the chromatography liquids is adjusted to 3.0 to 3.5, the chromatography liquids are preserved under 4 DEG C, and the collected chromatography liquids are mixed. Bubbles in the chromatographic column caused by degradation of carbonate are not likely to generate by using the preparation method. The preparation method is capable of increasing stage number and separation efficiency. The appearance of the obtained vancomycin is improved significantly, purity is as high as 99%, and the vancomycin can be taken orally or by injection.

Dry powder vancomycin compositions and methods for administering and preparing such compositions. A composition of the present disclosure may be administered to a subject via pulmonary administration in an amount effective to treat and/or prevent a bacterial infection in the subject. Administration of an effective amount of a composition of the present disclosure may be particularly useful in treating a gram-positive bacterial infection in a subject suffering from pneumonia, cystic fibrosis, bronchiectasis, or other chronic lung disease with a bacterial infection of the subject's airway and/or lung.

The invention provides a preserving fluid for preserving a virus sample at normal temperature for a long time. The preserving fluid is equipped whit nutrient substances such as salts, amino acids, glucose and the like required by virus survival, is added with virus protective agents such as polyvinylpyrrolidone, mannitol, trehalose and the like for protecting viruses, and is added with bacteriostatic agents such as amphotericin B, vancomycin and the like for inhibiting the growth of bacteria. The preserving fluid is safe and non-toxic, is simple to use, does not need cold chain preservation, can be used for transporting and preserving the virus sample at normal temperature for 3 days, and effectively solves the problems that the virus samples depend on cold chains in the sampling, transporting and preserving processes and the preservation time is short. The preserving fluid can maintain the primitiveness of the virus sample, is beneficial to comprehensive analysis and research of the virus sample, and is suitable for collection and transportation of epidemic virus samples.